StockFDA
AbbVie Wins FDA Approval to Start Skyrizi at Home: What the Crohn's Decision Means for ABBV Stock
2026-10-24
The FDA approved an at-home way to start one of AbbVie's biggest drugs on October 23, 2026 — and Wall Street barely blinked. AbbVie (NYSE: ABBV) closed Friday at $285.64, up just $0.45, or 0.16%, a...
Aardvark Stock Crashes 65% to a Record Low: The Trial Data That Erased a Rally in Hours
2026-10-23
Aardvark stock crashed 64.8% in one day — here is what happened Aardvark Therapeutics (NASDAQ: AARD) closed at $1.39 on Friday, October 23, 2026, down 64.8% in a single session and at a new 52-week...
Aardvark Therapeutics Stock Surges 24% Premarket After FDA Lifts Clinical Hold on ARD-101
2026-10-23
The Short Answer Aardvark Therapeutics (Nasdaq: AARD) jumped about 24% in premarket trading on Friday, October 23, 2026, after the U.S. Food and Drug Administration lifted the clinical hold on ARD-...
Biohaven Stock Surges 37%: FDA Gives Vyglxia a Second Chance After Last Year's Rejection
2026-10-22
Biohaven (NYSE: BHVN) stock surged as much as 39% in premarket trading on Thursday, October 22, 2026, after the U.S. Food and Drug Administration accepted the company's resubmitted application for...